Evaluation of Immunogenicity and Safety of Two 2-dose Human Papillomavirus (HPV) Vaccine Schedules in 9-14 Year Old Girls

NCT01381575 PHASE3 COMPLETED Results posted

This study has been designed to evaluate the immunogenicity and safety of GSK Biologicals' HPV-16/18 vaccine when administered according to alternative 2-dose schedules (0,6 months and 0,12 months) in healthy 9-14 year old females as compared to the standard 3-dose schedule (0,1,6 months) in 15-25 year old females.

Details

Lead sponsor	GlaxoSmithKline
Phase	PHASE3
Status	COMPLETED
Enrolment	1447
Start date	Wed Jun 29 2011 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Nov 13 2014 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Infections, Papillomavirus

Interventions

• GSK Biologicals' HPV vaccine 580299

Countries

Italy, Taiwan, Germany, Canada, Thailand